Quince Therapeutics, Inc. (QNCX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $28.87 (+6.89%), Market cap $0.02B, 52-week low–high $0.08 ~ $4.40.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprisin
Financial statements, price targets, institutional (13F) holdings and related news for Quince Therapeutics, Inc. are updated in real time on BlackAll Trade.
Quince Therapeutics, Inc. trades at $28.87 (+6.89%). Real-time quotes and charts are available on BlackAll Trade.
Quince Therapeutics, Inc. has a market cap of about $0.02B.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candid